| Q36919202 | A major mechanism of human immunodeficiency virus-induced cell killing does not involve cell fusion |
| Q35872502 | A mechanism of restricted human immunodeficiency virus type 1 expression in human glial cells |
| Q41651591 | A system for the high efficiency replication of HIV-1 in neural cells and its application to anti-viral evaluation |
| Q35842465 | Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes |
| Q41504287 | Analysis of long-term viral expression in CEM cells persistently infected with non syncytium-inducing HIV-1 strains |
| Q28367556 | Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor |
| Q45859981 | Contribution of multiple rounds of viral entry and reverse transcription to expression of human immunodeficiency virus type 1. A quantitative kinetic study |
| Q36881607 | Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual |
| Q36811913 | Differences in the basal activity of the long terminal repeat determine different replicative capacities of two closely related human immunodeficiency virus type 1 isolates |
| Q36919865 | Downregulation of cell surface molecules during noncytopathic infection of T cells with human immunodeficiency virus |
| Q45786698 | Human Immunodeficiency Virus Type 1 Infection Requires Reverse Transcription of Nascent Viral RNA |
| Q39880472 | Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro |
| Q40045880 | Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrested T cells. |
| Q41717436 | In vitro replication and cytopathogenicity of the feline immunodeficiency virus for feline t4 thymic lymphoma 3201 cells |
| Q42056169 | Inactivation of human immunodeficiency virus type 1 in blood samples stored as high-salt lysates. |
| Q28378556 | Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro |
| Q35861652 | Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4. |
| Q45847548 | Low-cytopathic infectious clone of human immunodeficiency virus type I (HIV-I). |
| Q28323316 | Modification of Human Immunodeficiency Viral Replication by Pine Cone Extracts |
| Q36919950 | Persistent productive infection of human glial cells by human immunodeficiency virus (HIV) and by infectious molecular clones of HIV. |
| Q37262269 | Productive nonlytic human immunodeficiency virus type 1 replication in a newly established human leukemia cell line |
| Q41745516 | Protease activation during HIV infection in a CD4-positive cell line |
| Q28646804 | Quantitative measurement of fusion between human immunodeficiency virus and cultured cells using membrane fluorescence dequenching |
| Q36685444 | Restoration of cell surface CD4 expression in human immunodeficiency virus type 1-infected cells by treatment with a Tat antagonist |
| Q42129695 | Specific induction of RGS16 (regulator of G-protein signalling 16) mRNA by protein kinase C in CEM leukaemia cells is mediated via tumour necrosis factor alpha in a calcium-sensitive manner |
| Q41453322 | Susceptibility of human glial cells to infection with human immunodeficiency virus (HIV). |
| Q41651088 | Temperature enhancement of syncytium formation by HIV and sendai virus |
| Q77977782 | Viral interference in HIV-1 infected cells |